araag2/HINT huggingface dataset:
Clinical trial NCT00066872 (phase 3, status: completed)
Conditions: non-melanomatous skin cancer
ICD codes: C79.2, C44.500, C44.90, D23.9, D48.5, C44.00, C44.301
Drugs: imiquimod
SMILES: CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary basal cell skin carcinoma

               -  Nodular or superficial lesion(s)*

               -  Located in low-risk areas NOTE: *Any number of lesions are allowed but only 1
                  lesion per patient is selected for the study

          -  No genetic or nevoid conditions (e.g., Gorlin's syndrome)

          -  No morphoeic (microinfiltrative) histology

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  No bleeding disorder

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for up to 1 month after
             study participation

          -  No allergy to any of the study interventions

          -  No life-threatening disease

          -  Must be available for study follow-up for up to 3 years

          -  Must have access to a telephone

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in any other experimental trial
Clinical trial NCT00330876 (phase 3, status: completed)
Conditions: hypercholesterolemia, dyslipidemias
ICD codes: E78.01, E78.00, Z83.42
Drugs: pitavastatin
SMILES: O[C@H](C[C@H](O)\C=C\C1=C(N=C2C=CC=CC2=C1C1=CC=C(F)C=C1)C1CC1)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Greater than or equal to 65 years of age

          -  Primary hypercholesterolemia

          -  Combined dyslipidemia

          -  Completed study NK-104-306 (NCT00257686)

        Exclusion Criteria:

          -  Failed to complete study NK-104-306(NCT00257686)
Clinical trial NCT00210873 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: topiramate
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of chronic migraine

          -  successfully finished double-blind portion of the CAPSS-276 study or discontinued the
             study after a minimum of 4 weeks maintenance treatment due to lack of effect of study
             drug

          -  in generally good health

          -  able to take medicine orally

          -  if female, using birth control.

        Exclusion Criteria:

          -  Cannot have a more painful condition than the headache pain

          -  cannot be taking any other medications not allowed by the study protocol

          -  no abnormal liver tests

          -  not compliant with study medication during the CAPSS-276 study

          -  cannot be pregnant or breast-feeding.
Clinical trial NCT00347048 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: tacrolimus, placebo
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Moderate to severe refractory UC patients

          -  Disease activity: more than 4 times of stool a day, bloody stool, moderate to severe
             endoscopic finding

          -  Steroid resistance or dependence to meet at least one of the following condition:no
             efficacy with more than 40mg/day or 1mg/kg/day of steroid over at least 1 week, no
             efficacy with 30-40mg/day of steroid over at least 2 weeks,exacerbation along with
             steroid reduction

        Exclusion Criteria:

          -  Mild or fulminant type

          -  Renal failure patients, hepatic failure patients

          -  Patients taking 6-mercaptopurine, cyclosporin or other immunosuppressants within 12
             weeks prior to entry

          -  Patients who received LCAP or GCAP within 2 weeks prior to entry

          -  Patients who changed the dose of steroid or started steroid within 2 weeks prior to
             entry.

          -  Patients who changed the dose of steroid or started steroid within 1 week prior to
             entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before
             the study.
Clinical trial NCT00358436 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe
             stable COPD

        Exclusion Criteria:

          -  History or current diagnosis of asthma, recent respiratory tract infection or acute
             COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic
             hypertrophy, bladder neck obstruction or narrow-angle glaucoma
Clinical trial NCT00435019 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin detemir, insulin nph, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Insulin detemir naive

          -  Type 1 diabetes for at least 12 months

          -  HbA1c lesser than or equal to 11.0%

        Exclusion Criteria:

          -  Significant concomitant diseases
Clinical trial NCT01166178 (phase 3, status: terminated)
Conditions: osteoporosis, multiple sclerosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS, G35, C81.18
Drugs: zoledronic acid, placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion:

          -  Written informed consent to participate in the trial

          -  Definite diagnosis of Multiple Sclerosis (MS) as defined by 2005 revised McDonald
             criteria

          -  MS-subtype: Relapsing-remitting MS (RRMS), Secondary progressive MS (SPMS), Primary
             progressive MS (PPMS)

          -  Expanded Disability Status Scale (Kurtzke's scale; EDSS) score between 2.5 to 6.5
             (including both)

          -  Bone mineral density (BMD) T-score of less or equal to -2.0 and more or equal to -4.0
             at the lumbar spine (L1-L4 with at least 2 evaluable vertebrae) and/or total hip
             region and/or femoral neck in recent Dual X-Ray Absorptiometry (DXA)-scan (< or = 3
             months)

          -  Sufficient ability to read, write and communicate comprehensibly and comply to study
             procedures

          -  No immunomodulatory treatment for MS within the last 30 days or stable and well
             tolerated therapy with any beta-interferon formulation, or glatirameracetate or
             fingolimod for at least 30 days immediately prior to baseline

        Exclusion criteria:

          -  Contraindications against Calcium and Vitamin D and zoledronic acid according to the
             summary product characteristics

          -  More than one osteoporotic fracture

          -  Concomitant medication with influence on bone mineral density (eg. enzyme- inducing
             antiepileptics like Carbamazepin, Phenytoin, Phenobarbital, Primidon)

          -  Any neurological disorder other than MS which is known to affect bone mineral density
             (e.g. muscular dystrophy, severe paresis for other reasons than MS, degenerative
             nervous disorder, stroke)

          -  Women who are pregnant or breast feeding, or menstruating and capable of becoming
             pregnant.

          -  Baseline renal insufficiency

          -  25-OH vitamin D level < 10 ng/ml at screening

          -  Serum calcium levels > 2.75 mmol/l (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL) at
             screening

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00652106 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, concurrent brimonidine 0.2% and timolol 0.5% ophthalmic solution, brimonidine 0.2% ophthalmic solution
SMILES: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ocular hypertension or glaucoma

          -  Patient requires IOP-lowering therapy in both eyes

        Exclusion Criteria:

          -  Uncontrolled medical conditions

          -  Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
Clinical trial NCT00525798 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: smc021 oral calcitonin, smc021 placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women with osteoporosis, ambulatory, in general good health, not
             receiving medication that affects bone metabolism, and free from any underlying
             condition, other than osteoporosis, that may result in abnormal bone metabolism.

        Exclusion Criteria:

          -  BMD T-score below -4.0 (based on absolute values g/cm2 as given in the protocol) at
             one or more of the measured sites

          -  More than 2 prevalent vertebral fractures (Genant et al, 15).

          -  If BMD is lower than -2.5 T-score at one or more of the measured sites, the
             participants will be excluded from the study, if they have a severe vertebral fracture
             (Genant et al, 15).

          -  Evidence of any clinical osteoporotic fracture and/or if they have a history of a
             clinical osteoporotic fracture (excluding wrist fractures)

          -  BMD T-score > -1.5 in all of the following regions: Lumbar spine, femoral neck or
             total hip.

        Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT00391807 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: norethindrone acetate/ethinyl estradiol
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy Women

          -  Age 18-45

          -  At risk for pregnancy

          -  History of regular cycles

        Exclusion Criteria:

          -  Contraindications for use of hormonal contraception

          -  Conditions which affect the absorption or metabolism of steroid hormones

          -  BMI > 35
Clinical trial NCT00564512 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclophosphamide, fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

        Inclusion

        Diagnosis of B-cell chronic lymphocytic leukemia (CLL), meeting the following criteria:

          -  Binet classification stages B or C

          -  Del 17 p (FISH) negative (< 10 % positives cores)

          -  Matutes score 4 or 5

        Exclusion Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma,
        Hodgkin lymphoma, or prolymphocytic leukemia)

        PATIENT CHARACTERISTICS:

        Exclusion ECOG performance status ≥ 2

          -  Life expectancy < 6 months

          -  Creatinine clearance < 60 mL/min

          -  Total bilirubin > 2 x upper limit of normal (ULN)

          -  Gamma glutamyltransferase or transaminase levels > 2 x ULN

          -  Cumulative illness rating scale > 6

          -  HIV seropositivity

          -  Hepatitis B or C seropositivity (unless clearly due to vaccination)

          -  Clinically significant autoimmune anemia

          -  Active bacterial, viral, or fungal infection

          -  Active second malignancy currently requiring treatment (except basal cell carcinoma or
             in situ endometrial carcinoma) and/or less than 5 years complete remission after
             breast cancer

          -  Any severe comorbid conditions including, but not limited to, any of the following:

               -  Class III or IV heart failure

               -  Recent myocardial infarction

               -  Unstable angina

               -  Ventricular tachyarrhythmias requiring ongoing treatment

               -  Severe chronic obstructive pulmonary disease with hypoxemia

               -  Uncontrolled diabetes mellitus

               -  Uncontrolled hypertension

          -  Concomitant disease requiring prolonged use of corticosteroids (> 1 month)

          -  Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies
             or any of the study drugs

          -  Contraindication to the use of rituximab or alemtuzumab according to Summary of
             Product Characteristics

          -  Any coexisting medical or psychological condition that would preclude participation in
             the required study procedures

          -  Any mental deficiency preventing proper understanding of the requirements of treatment

          -  Person under law control

          -  Pregnant or breastfeeding women

          -  Fertile patients who cannot or do not wish to use an effective method of
             contraception, during and for 12 months after the final treatment used for the
             purposes of the study

        PRIOR CONCURRENT THERAPY:

        Inclusion

          -  No prior chemotherapy, radiotherapy, or immunotherapy for CLL

          -  Corticosteroids within the past month allowed
Clinical trial NCT00147355 (phase 3, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: ondansetron, ibuprofen, paracetamol, ondansetron, ibuprofen, paracetamol, metoclopramide, ibuprofen, paracetamol, metoclopramide, codeine phosphate, ibuprofen, paracetamol
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC, [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Reason stopped: 
    28 of 168 patients only were enrolled, numbers too low to be conclusive
  
Eligibility criteria:

        Inclusion Criteria:

        Patients participating in ESPRIT and randomised to the rIL-2 arm, who:

          1. Are not at CD4+ T-cell target for the protocol

          2. Have not received rIL-2 for > 2 months

          3. Have reported both GI upset and constitutional side-effects as one of the reasons for
             either dose modifying in prior cycles or unwillingness to receive further rIL-2

          4. Are considered by the Investigator as medically safe to receive further dosing with
             rIL-2

          5. Are willing to receive further dosing with rIL-2 at the dose specified by the
             Investigator

          6. Are willing to sign informed consent to participate in the substudy

        Exclusion Criteria:

          1. All exclusions for the receipt of rIL-2 on ESPRIT

          2. Known allergy to non-steroidal anti-inflammatory drugs (NSAIDs), opiates, 5HT-3
             (serotonin-3) inhibitors, anti-dopaminergic antiemetics, or any other components of
             the proposed adjunct regimens.

          3. Use of other NSAIDs (cyclooxygenase-2 [COX-2] inhibitors, corticosteroids) or opiate
             analgesics within two weeks of rIL-2 dosing. Use of low dose aspirin as a
             cardio-protective agent is allowed.
Clinical trial NCT00175903 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: levetiracetam, carbamazepine controlled release (cbz-cr), valproate extended release
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12, CCCC(CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of epilepsy (all types of seizures) was made during the past year

          -  Subjects must have had at least two unprovoked seizures in the past 2 years with at
             least one during the last 6 months

          -  Female subjects without childbearing potential are eligible. Female subjects with
             childbearing potential are eligible if they use a medically accepted contraceptive
             method

        Exclusion Criteria:

          -  Subjects previously allocated to a trial treatment (CBZ, VPA and LEV) used in this
             trial

          -  Participation in another clinical trial with an investigational drug or device within
             12 weeks of the selection visit (V1), or at any time during this trial

          -  Pregnant or lactating women

          -  Presence of known pseudoseizures within the last year

          -  Uncountable seizures (clusters) or history of convulsive status epilepticus

          -  Any disorder or condition that may interfere with the absorption, distribution,
             metabolisation or excretion of drugs

          -  History of suicide attempt, current suicidal ideation, or other serious psychiatric
             disorders requiring or having required hospitalization or medication within the
             previous five years

          -  Presence of progressive cerebral disease, any other progressively degenerative
             neurological disease, or any cerebral tumors

          -  Presence of a terminal illness or any medical condition that might interfere with the
             subject's trial participation
Clinical trial NCT01281527 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

        Meet the DSM-IV criteria for schizophrenia Currently non-acute, i.e., on the same
        antipsychotic medication used for the treatment of schizophrenia given in an adequate dose
        and a CGI-S change <= 1 in the past 4 weeks before enrollment Patient has been given an
        adequate dose of either an appropriate oral antipsychotic, or a protocol-defined LAI
        antipsychotic for an adequate period of time prior to enrollment, but current treatment is
        considered unsuccessful OR Patients with acute symptoms of schizophrenia, previously
        treated with an oral antipsychotic, having a baseline total Positive and Negative Syndrome
        Scale (PANSS) score >= 80 and a baseline CGI-S score >= 4 Women must be postmenopausal for
        at least 1 year, surgically sterile, abstinent (at the discretion of the investigator/per
        local regulations), or if sexually active, be practicing a highly effective method of birth
        control as local regulations permit, and before entry, must agree to continue to use the
        same method of contraception throughout the study Is cooperative and reliable, and agrees
        to receive regular injections and complete all aspects of the protocol Men must agree to
        use a double barrier method of birth control and to not donate sperm during the study and
        for 3 months after receiving the last dose of study drug.

        Exclusion Criteria:

        The patient's psychiatric diagnosis is due to direct pharmacological effects of a substance
        (e.g., a drug of abuse or medication) or a general medical condition (e.g., clinically
        notable hypothyroidism) First antipsychotic treatment ever, i.e., patient has never been
        treated with antipsychotics before and antipsychotic treatment given in this study will be
        the first antipsychotic treatment that the patient will have ever received On clozapine
        during the last 3 months Patients who remain at imminent risk of suicide even after
        clinical intervention Serious unstable medical condition, including recent and present
        clinically relevant laboratory abnormalities
Clinical trial NCT00199394 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: istradefylline (kw-6002)
SMILES: [H]\C(=C(\[H])C1=CC(OC)=C(OC)C=C1)C1=NC2=C(N1C)C(=O)N(CC)C(=O)N2CC
Eligibility criteria:

        Inclusion Criteria:

        Patients selected for this study will be at least 30 years of age and will have been
        diagnosed with advanced Parkinson's disease as determined by UK Parkinson's Disease Society
        (UKPDS) criteria and the Modified Hoehn and Yahr Scale. The patients will have been
        receiving levodopa treatment for at least one year, may be taking other antiparkinsonian
        drugs, will have an average of at least three hours OFF time as recorded in two 24-hour
        ON/OFF diaries, and if female, must be non-pregnant and non-nursing.

        Exclusion Criteria:

        Patients may not be enrolled if they are taking certain medications excluded by the
        protocol, have been treated with any investigational drug within 30 days prior to
        randomisation (or five half-lives if longer), have ever received istradefylline or been
        treated with a COMT inhibitor, are psychotic, have clinically significant illness or
        laboratory values at screening, have insufficient mental capacity to comply with protocol
        requirements or certain psychiatric or neurological conditions.

        -
Clinical trial NCT00048074 (phase 3, status: completed)
Conditions: post menopausal osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: ibandronate [bonviva/boniva], ibandronate [bonviva/boniva], ibandronate [bonviva/boniva]
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  women 55-80 years of age;

          -  post-menopausal for >=5 years;

          -  ambulatory.

        Exclusion Criteria:

          -  malignant disease diagnosed within the previous 10 years (except basal cell cancer
             that has been successfully removed);

          -  breast cancer within the previous 20 years;

          -  allergy to bisphosphonates;

          -  previous treatment with an intravenous bisphosphonate at any time;

          -  previous treatment with an oral bisphosphonate within the last 6 months, >1 month of
             treatment within the last year, or >3 months of treatment within the last 2 years.